Related Experiment Videos
Malignant mesothelioma--the UK experience
1Royal Marsden NHS Trust, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK. maryo@icr.ac.uk
Lung Cancer (Amsterdam, Netherlands)
|July 21, 2004
Summary
Mesothelioma deaths are rising in Britain. A new trial investigates early versus delayed chemotherapy, comparing MVP or vinorelbine regimens with active symptom control alone for malignant mesothelioma treatment.
Area of Science:
- Oncology
- Respiratory Medicine
- Clinical Trials
Background:
- Mesothelioma mortality in Britain is projected to increase significantly.
- A natural history database provides a foundation for mesothelioma research.
- Current UK chemotherapy regimens include mitomycin, vinblastine and cisplatin (MVP) or vinorelbine.
Purpose of the Study:
- To evaluate early versus delayed chemotherapy in mesothelioma treatment.
- To compare chemotherapy regimens (MVP or vinorelbine) with active symptom control (ASC) alone.
- To explore novel agents in combination with chemotherapy for malignant mesothelioma.
Main Methods:
- A new clinical trial at The Royal Marsden is investigating treatment timing.
- Data from existing trials on MVP and vinorelbine regimens are being utilized.
- A national trial is proposed comparing chemotherapy plus ASC versus ASC alone.
Main Results:
- SRL172 shows potential benefits when combined with chemotherapy.
- Baseline data on mesothelioma natural history are established.
- UK chemotherapy practices for mesothelioma are documented.
Conclusions:
- Early versus delayed chemotherapy is a novel treatment approach for mesothelioma.
- National collaboration (BMIG) is advancing mesothelioma clinical trials.
- Combination therapy with novel agents like SRL172 warrants further investigation.